Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Epigenetic alterations in osteosarcoma: promising targets.

Literature DB >> 24500341

Epigenetic alterations in osteosarcoma: promising targets.

Abstract

Cancer is being reinterpreted due to recent discoveries related to epigenetic regulation during development, and the importance of epigenetic mechanisms in initiation and progression of cancer has been further highlighted by the recent explosion in medical information. Osteosarcoma is highly genetically unstable, and current therapeutic regimens are subject to chemoresistance and tumor relapse. Understanding the epigenetic mechanisms in the pathogenesis of osteosarcoma will provide novel avenues for cancer therapy. In this review, we examine the epigenetic alterations in gene expression in osteosarcoma, and discuss the utilization of epigenetic regulation therapy in treatment against osteosarcoma.

Entities: Disease

Mesh：

Year: 2014 PMID： 24500341 DOI： 10.1007/s11033-014-3193-7

Source DB: PubMed Journal: Mol Biol Rep ISSN： 0301-4851 Impact factor: 2.316

158 in total

Review 1. Epigenetic therapy of cancer: past, present and future.

Authors: Christine B Yoo; Peter A Jones
Journal: Nat Rev Drug Discov Date: 2006-01 Impact factor: 84.694

Review 2. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

Authors: Guillermo Garcia-Manero; Pierre Fenaux
Journal: J Clin Oncol Date: 2011-01-10 Impact factor: 44.544

3. miR-16 inhibits cell proliferation by targeting IGF1R and the Raf1-MEK1/2-ERK1/2 pathway in osteosarcoma.

Authors: Lei Chen; Qing Wang; Guo-dong Wang; Hua-song Wang; Yong Huang; Xi-ming Liu; Xian-hua Cai
Journal: FEBS Lett Date: 2013-03-15 Impact factor: 4.124

4. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine.

Authors: Julianne L Holleran; Robert A Parise; Erin Joseph; Julie L Eiseman; Joseph M Covey; Elizabeth R Glaze; Alexander V Lyubimov; Ya-Fei Chen; David Z D'Argenio; Merrill J Egorin
Journal: Clin Cancer Res Date: 2005-05-15 Impact factor: 12.531

5. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

Authors: Yasuhiro Oki; Hagop M Kantarjian; Vazganush Gharibyan; Dan Jones; Susan O'brien; Srdan Verstovsek; Jorge Cortes; Gail M Morris; Guillermo Garcia-Manero; Jean-Pierre J Issa
Journal: Cancer Date: 2007-03-01 Impact factor: 6.860

Review 6. The RASSF1A tumor suppressor.

Authors: Howard Donninger; Michele D Vos; Geoffrey J Clark
Journal: J Cell Sci Date: 2007-09-15 Impact factor: 5.285

7. Neonatal diethylstilbestrol exposure induces persistent elevation of c-fos expression and hypomethylation in its exon-4 in mouse uterus.

Authors: Shuanfang Li; Roberta Hansman; Retha Newbold; Barbara Davis; John A McLachlan; J Carl Barrett
Journal: Mol Carcinog Date: 2003-10 Impact factor: 4.784

8. A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium.

Authors: Alexandra P Zorzi; Mark Bernstein; Yvan Samson; Donna A Wall; Sunil Desai; Darcy Nicksy; Nancy Wainman; Elizabeth Eisenhauer; Sylvain Baruchel
Journal: Pediatr Blood Cancer Date: 2013-07-25 Impact factor: 3.167

9. MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xL and Mcl-1.

Authors: Fang Ji; Hao Zhang; Yang Wang; Ming Li; Weidong Xu; Yifan Kang; Zhiwei Wang; Zimin Wang; Ping Cheng; Dake Tong; Cheng Li; Hao Tang
Journal: Bone Date: 2013-06-10 Impact factor: 4.398

10. Increased methylation variation in epigenetic domains across cancer types.

Authors: Kasper Daniel Hansen; Winston Timp; Héctor Corrada Bravo; Sarven Sabunciyan; Benjamin Langmead; Oliver G McDonald; Bo Wen; Hao Wu; Yun Liu; Dinh Diep; Eirikur Briem; Kun Zhang; Rafael A Irizarry; Andrew P Feinberg
Journal: Nat Genet Date: 2011-06-26 Impact factor: 38.330

18 in total

Review 1. Molecular genetics of osteosarcoma.

Authors: Kirby Rickel; Fang Fang; Jianning Tao
Journal: Bone Date: 2016-10-17 Impact factor: 4.398

Review 2. Deciphering signaling networks in osteosarcoma pathobiology.

Authors: Christos Adamopoulos; Antonios N Gargalionis; Efthimia K Basdra; Athanasios G Papavassiliou
Journal: Exp Biol Med (Maywood) Date: 2016-05-06

Review 3. Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.

Authors: James J Morrow; Chand Khanna
Journal: Crit Rev Oncog Date: 2015

Review 4. Autophagy in Osteosarcoma.

Authors: Grace Nehme; Nancy Gordon
Journal: Adv Exp Med Biol Date: 2020 Impact factor: 3.650

5. Histone Deacetylase Inhibitor Trichostatin a Promotes the Apoptosis of Osteosarcoma Cells through p53 Signaling Pathway Activation.

Authors: Zhantao Deng; Xiaozhou Liu; Jiewen Jin; Haidong Xu; Qian Gao; Yong Wang; Jianning Zhao
Journal: Int J Biol Sci Date: 2016-10-18 Impact factor: 6.580

6. Ras-Association Domain Family 1 Isoform A (RASSF1A) Gene Polymorphism rs1989839 is Associated with Risk and Metastatic Potential of Osteosarcoma in Young Chinese Individuals: A Multi-Center, Case-Control Study.

Authors: Hongwei Xu; Wang Zhan; Zhiyuan Chen
Journal: Med Sci Monit Date: 2016-11-23

Review 7. Osteosarcoma: prognosis plateau warrants retinoblastoma pathway targeted therapy.

Authors: Sarah E Ballatori; Philip W Hinds
Journal: Signal Transduct Target Ther Date: 2016-03-25

8. Polymorphisms of the Ras-Association Domain Family 1 Isoform A (RASSF1A) Gene are Associated with Ovarian Cancer, and with the Prognostic Factors of Grade and Stage, in Women in Southern China.

Authors: Wei He; Pengyuan Zhang; Min Ye; Zhikang Chen; Yizi Wang; Jie Chen; Fengjuan Yao
Journal: Med Sci Monit Date: 2018-04-19

9. Associations of polymorphisms in NAT2 gene with risk and metastasis of osteosarcoma in young Chinese population.

Authors: Zhengxiang Huang; Li Yuan; Zhenghui Jiang; Dongliang Wang
Journal: Onco Targets Ther Date: 2015-09-22 Impact factor: 4.147

Review 10. Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors.

Authors: Katia Scotlandi; Claudia Maria Hattinger; Evelin Pellegrini; Marco Gambarotti; Massimo Serra
Journal: Cells Date: 2020-04-14 Impact factor: 6.600